PubRank

Srinivas V Kaveri

Author PubWeight™ 38.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Transition towards antigen-binding promiscuity of a monospecific antibody. Mol Immunol 2006 1.54
2 Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood 2010 1.53
3 VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2006 1.20
4 Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008 1.05
5 Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J Biol Chem 2005 0.98
6 Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. Drug Discov Today 2011 0.97
7 Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J Biol Chem 2007 0.97
8 Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS J 2010 0.95
9 Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010 0.95
10 The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2013 0.93
11 A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci U S A 2007 0.92
12 Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors. Immunol Lett 2007 0.91
13 Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J Immunol 2005 0.89
14 Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. J Immunol 2008 0.86
15 Antibody polyreactivity in health and disease: statu variabilis. J Immunol 2013 0.85
16 Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. Blood 2009 0.85
17 Functional variability of antibodies upon oxidative processes. Autoimmun Rev 2008 0.85
18 Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. Biochemistry 2012 0.84
19 Important parameters for evaluation of antibody avidity by immunosorbent assay. Anal Biochem 2011 0.84
20 Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 2007 0.83
21 Heme interacts with c1q and inhibits the classical complement pathway. J Biol Chem 2011 0.82
22 Heterogeneous antigen recognition behavior of induced polyspecific antibodies. Biochem Biophys Res Commun 2010 0.82
23 Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clin Vaccine Immunol 2008 0.82
24 Multiple antigenic mimotopes of HIV carbohydrate antigens: relating structure and antigenicity. J Biol Chem 2006 0.81
25 Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation. Thromb Haemost 2010 0.81
26 A cellular viewpoint of anti-FVIII immune response in hemophilia A. Clin Rev Allergy Immunol 2009 0.81
27 Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. FEBS Lett 2009 0.81
28 Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? Br J Haematol 2011 0.80
29 The role of VWF in the immunogenicity of FVIII. Thromb Res 2008 0.80
30 Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol 2008 0.80
31 "Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies. PLoS Pathog 2011 0.79
32 IVIg treatment reduces catalytic antibody titers of renal transplanted patients. PLoS One 2013 0.79
33 Immunotherapy of viral infections. Immunotherapy 2009 0.79
34 Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity. PLoS One 2013 0.77
35 Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells. J Allergy Clin Immunol 2012 0.77
36 Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica 2013 0.77
37 Catalytic antibodies and severe sepsis. Discov Med 2005 0.76
38 Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Mol Immunol 2009 0.76
39 Natural and Induced Antibody Polyreactivity. Anticancer Agents Med Chem 2015 0.76
40 Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G. Blood Coagul Fibrinolysis 2006 0.76
41 [Post-translational diversification of immunoglobulins specificity]. Med Sci (Paris) 2013 0.76
42 Gain of function of immunoglobulins after partial unfolding or cofactor binding. Mol Immunol 2013 0.76
43 Human mannose receptor (CD206) in immune response: novel insights into vaccination strategies using a humanized mouse model. Expert Rev Clin Immunol 2007 0.75
44 Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice. Immunology 2010 0.75
45 Auditing protein therapeutics management by professional APCs: toward prevention of immune responses against therapeutic proteins. J Immunol 2008 0.75
46 Correction to Mechanism and functional implications of the heme-induced binding promiscuity of IgE. Biochemistry 2015 0.75
47 Antibodies with hydrolytic activity towards factor VIII in patients with hemophilia A. J Immunol Methods 2002 0.75
48 Insight into the mechanism of the acquired antibody auto-reactivity. Autoimmun Rev 2008 0.75